Name
GS01-02 - Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2 - breast cancer: KEYNOTE-756 (China)
Date & Time
Wednesday, December 20, 2023
Speakers
Virtual Session Link